ANRS 12406 EvvA Study (EvvA)
Virological Failure and HIV Drug Resistance Among Adolescents Receiving Antiretroviral Treatment in Cameroon
ANRS 12406 EvvA is an observational, longitudinal and monocentric study evaluating the virological success rate in HIV-infected adolescents on antiretroviral therapy in Cameroon.
The main objective of the study is to estimate the rate of virological suppression among adolescents on antiretroviral therapy for more than 6 months in Cameroon
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
At the end of 2017, HIV-AIDS affects more than 36 million people worldwide, more than three-quarters of whom live in sub-Saharan Africa, and a quarter of the infections are among young people and adolescents. Every hour, 4 adolescents (aged 15-19) are newly infected with HIV in the world, and 3 of them are adolescents. Three infections occur in sub-Saharan Africa, and for five adolescents living with HIV, there are seven girls (aged 10 to 19) in the same situation. This gender disparity increases when adolescents reach adulthood. This group of the population may well deserve the term "key and vulnerable population". In the era of international commitment to end the AIDS epidemic by 2030, especially to stop new infections, it is essential not to neglect part of the epidemic because it would effectively represent a reservoir for maintaining the epidemic and make these eradication goals impracticable. Data on virological success among adolescents on antiretroviral treatment are generally scarce and this is much more striking in Central Africa. Also, information on the frequency of emergence of resistant viruses and the consequences for the effectiveness of available treatments is rare. However, in the absence of such data, it is difficult, if not impossible, to take the right decisions to improve the care and monitoring of adolescents. In addition, the few available data indicate high virological failure rates and high frequencies of drug resistance, which may indicate a need to further investigate virological failure events in this population.
This study will be conducted in Cameroon among 289 adolescents during 9 months, where access to biological monitoring is a major challenge, especially with low access to viral load testing. The results of this project will inform on the current state of success of ARV treatments in this population. Moreover, the other goal of this study is to conclude on the need to conduct a larger study at the national or regional level according to the results obtained
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studiecontact
- Naam: Avelin F AGHOKENG, PhD
- Telefoonnummer: +(33)467415958
- E-mail: avelin.aghokeng@ird.fr
Studie Contact Back-up
- Naam: Ida C Penda, PhD
- Telefoonnummer: +(237)7770 31 55
- E-mail: calix.penda@gmail.com
Studie Locaties
-
-
-
Douala, Kameroen
- Werving
- Hôpital Laquinitie de Douala
-
Contact:
- Ida C Penda, PhD
- Telefoonnummer: +(237)7770 31 55
- E-mail: calix.penda@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Being adolescent (aged 10 to 19) on antiretroviral therapy and followed at the Laquintinie Hospital (Douala Cameroon)
- HIV-1 infection
- Duration of antiretroviral therapy ≥ 6 months regardless of antiretroviral regimen
- For emancipated adolescents: obtaining informed consent signed by the adolescent
- For unemancipated adolescents:
- Obtaining informed consent signed by the legal representative (parent(s) or guardian(s))
- Obtaining the assent of adolescents able to understand the study (maturity and knowledge of HIV status)
Exclusion Criteria:
- Infection with HIV-1 or HIV-1/HIV2 co-infection
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Cohort
- Tijdsperspectieven: Dwarsdoorsnede
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Viral load suppression after ≥ 6 months of antiretroviral therapy
Tijdsspanne: Day 0
|
Proportion of participants with HIV-1 RNA <1000 copies / ml after ≥ 6 months of antiretroviral therapy
|
Day 0
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Drug resistance after ≥ 6 months of antiretroviral therapy
Tijdsspanne: 3 months
|
Proportion of participants with HIV-1 RNA ≥ 300 copies / ml and presence of antiretroviral-resistant virus (ARV) after ≥ 6 months of antiretroviral therapy
|
3 months
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Studie directeur: Avelin F AGHOKENG, PhD, Institut de Recherche pour le Developpement
- Hoofdonderzoeker: Ida C PENDA, Hôpital Laquinitie de Douala
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- ANRS 12406 EvvA
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .